Expanding the Effectiveness of Medical Procedures and Diagnosis

DH Medical is an early-stage medical software company using patented and tested methodologies and techniques to radically improve current limits of medical imaging, signal measurement and analysis.

Our products are designed to improve diagnostic accuracy, patient and provider safety and create new paradigms for therapies, treatment and care.

DH Medical launch product families have been chosen for maximum impact, easy integration into current systems and workflows, as well as providing the foundation for growth into other areas of life science innovation, new diagnostic and treatment patterns and other industries.

DH Medical PurePixel

A Revolutionary Breakthrough in Radiation Reduction in Fluoroscopy

“While radiation for CT, angio or fluoroscopy, no radiation is good radiation. My goal is to minimize radiation exposure for myself, my team, and my patients. Although we have no immediate indication of how much radiation we are exposed to – we all know the effects are cumulative, and when feeling effects like cancer, it’s too late. A neurointerventional radiology partner of mine died 2 years ago from a left-sided glioblastoma, undoubtably related to high radiation exposure over 30 years in practice. Technology that can reduce radiation while maintaining image quality is absolutely worth considering.”

Ryan Majoria, M.D. - Interventional and Diagnostic Radiologist, Radiology Associates, L.L.C., Baton Rouge, LA

For over a century, radiographic image clarity has been directly tied to the amount of radiation used. In fluoroscopic procedures, contrast agents are often added to improve soft tissue visibility—but they can also cause nausea, discomfort, allergic reactions, kidney damage, arrhythmias, or, in rare cases, cardiac arrest and seizures.

Complex procedures often involve effective radiation doses of 5–40 mSv—equivalent to an additional 2 to 35 years of effective radiation exposure. This significantly increases long-term cancer risk, impacts surgeon and provider health, and limits safe surgical time for patients.

Three Approaches to Reducing the Impact of Radiation

DH Medical PurePixel In Action

DH Medical’s PurePixel is designed to significantly enhance image clarity and detail, reduce radiation exposure for patients, providers, and staff, shorten procedure times, and minimize the need for toxic contrast agents. Using a patented, brute-force mathematical approach, PurePixel adjusts pixel intensities directly from the input signal—resulting in improved diagnostic accuracy, stronger AI analysis, and better clinical outcomes.

PurePixel is not machine-learned or model-trained. It uses non-convolutional, kernel-based operations derived from regional and global statistical properties of the image or video. The original photogrammetry remains untouched, while visual clarity—particularly in fluoroscopic imaging and diagnostics—is dramatically improved.

PurePixel’s effectiveness has already been demonstrated in other high-stakes industries:

DH Medical Precision Measuring Matrix (PMM)

DH Medical’s Product to Radically Improve Data Analysis to Change Cardiology and Prevent Congestive Heart Failure

Cardiac events are part of a continuous, complex process—not isolated peaks. Yet many current methods only detect the most obvious disruptions, such as heart failure. Our enhanced signal processing captures significantly more data with higher fidelity, increasing the potential for accurate analysis and early diagnosis.

By uncovering previously undetected signals in ECG streams, we provide richer inputs for both clinical interpretation and our proprietary AI engine. What’s typically dismissed as noise becomes valuable, actionable data—giving clinicians earlier insights and improving treatment pathways.

Our patented Precision Measuring Matrix (PMM) captures time, frequency, and amplitude (TFA) data simultaneously, enabling advanced multi-dimensional analysis and precise separation of complex biological signals.

Remote Cardiac Monitors Produce Excessive False Positives

The trend in remote cardiac monitoring is hugely impactful, but limited by data analysis, false positives, and device battery life. DH Medical testing in 2024 indicates that the PMM can help eliminate nearly all false positives.

Systemic Chronic Heart Disease Requires Earlier Detection & Diagnosis

Conditions such as Congestive Heart Failure (CHF) are chronically un-detected with current techniques. The DH Medical PMM increases the amount of available data, ability to analyze it, and improve AI model outcomes by an order of magnitude.

DH Medical CytoAcoustics

Cells move and vibrate generating unique acoustic signals. Healthy and diseased cells have fundamentally different profiles. CytoAcoustics can measure this.

“CytoAcoustics’ groundbreaking discovery has the potential to significantly advance the speed and accuracy of diagnosis and treatment selection for cancer and other diseases.”

“CytoAcoustics is the first company in the field of precision acoustic medicine with a technology that could change modern biology.”

Dr. William Nelson, MD, PhD, Chair, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

About DH Medical

Background & Origins of Our Technology

Digital Harmonic was developed in 2016 by Paul Reed Smith, founder of PRS Guitars. Paul experimented with novel approaches to measuring waveforms which led to technologies that began to truly revolutionize the practice of signal and imaging processing with the launch of three core Digital Harmonic products:

Paul’s inventions became the origins of Digital Harmonic’s technology stack. Additional product solutions for extracting and analyzing signals across time, frequency and amplitude, as well as digital video, were launched with applications in defense, broadcasting, data processing, product development, and with the launch of DHM, healthcare diagnostics and surgical medicine applications.

Digital Harmonic holds 39 patents and has a suite of solutions in-market with government and private video broadcast customers, as well as dozens of additional R&D projects in the pipeline together with DH Medical.

DH Medical Team

Jim Alecxih

Board Member
Jim brings a rich 35-year history in the medical device industry, including working with Intuitive Surgical from first revenue to over $2B in sales. Extensive product launch, early stage, and high growth experience and several successful go-to-market launches.
Paul Reed Smith

Co-Founder, Head of Innovation
Paul Reed Smith is a guitar maker, musician, founder, and Managing General Partner of Paul Reed Smith Guitars.
He is the founder of Digital Harmonic, DH Medical, CytoAcoustics and Biosonic Acoustics.
Scott Haiges

Co-Founder, EVP Strategy
Scott has served as the CEO of Digital Harmonic since its inception, driving the company from initial concept through the commercialization of its products. Scott co-founded DH Medical after years of refining product-market fit.
Prior to joining Digital Harmonic, Scott was EIR at the venture capital firm Aspire Ventures, joining after a successful exit of a medical marketing technology company that he founded.
Dan Armstrong

COO
Dan is an experienced start-up and technology leader working in medtech, mobile telecommunications, satellite and financial services for 30+ years, with successful launches in over 40 countries.
He has worked in CGM insulin-delivery diabetes tech, design of innovative orthopedic surgery centers, early-stage fractal image format patents, and has a background in physics and audio engineering.
Mason Baron

CTO
With years of software development, AI, machine learning, surveillance reconnaissance systems design, imagery, signal, and radar processing experience, Mason leads DHM as CTO.
Mason served as Chief Engineer of Battle Force Projects at the Johns Hopkins University Applied Physics Laboratory prior to serving as Minotaur Chief Naval Architect at Alion Science & Technology.